# Table of Contents

**Universal Contraindications** ................................................................. 4

**Kidney including Kidney/Liver, Kidney/Heart & Kidney/Lung** ................. 7  
  - General Information ................................................................................. 7 
  - Indications ............................................................................................... 8 
  - Organ-specific Contraindications............................................................. 9 
  - Special Considerations .......................................................................... 9 

**Liver** ........................................................................................................ 12 
  - General Information ............................................................................... 12 
  - Indications ............................................................................................. 13 
  - Special Considerations ......................................................................... 15 

**Pancreas & Kidney/Pancreas** ................................................................. 19 
  - General Information ............................................................................... 19 
  - Indications ............................................................................................. 20 
  - Organ-specific Contraindications............................................................. 21 
  - Special Considerations ......................................................................... 21 

**Intestine including Liver/Intestine & Multivisceral** ................................. 26 
  - General Information ............................................................................... 26 
  - Indications ............................................................................................. 26 
  - Special Considerations ......................................................................... 27 

**Heart** ....................................................................................................... 30 
  - General Information ............................................................................... 30 
  - Indications ............................................................................................. 31 
  - Organ-specific Contraindications............................................................. 32 
  - Special Considerations ......................................................................... 32 
  - New York Heart Association (NYHA) Functional Classification ............ 34 

**Lung** ........................................................................................................ 38 
  - General Information ............................................................................... 38 
  - Indications ............................................................................................. 38 
  - Organ-specific Contraindications............................................................. 39 
  - Special Considerations ......................................................................... 39
# Table of Contents

Heart/Lung .................................................................................................................................... 42  
  General Information ........................................................................................................ 42  
  Indications ....................................................................................................................... 42  

Appendix ....................................................................................................................................... 43  
  National Kidney Foundation Definition of Chronic Kidney Disease (CKD)....................... 43
Universal Contraindications

**NOTE:** The following list contains the standard contraindications for solid organ transplants. These contraindications apply to ALL types of transplants unless otherwise noted. There may be additional contraindications that apply to a specific type of transplant. Please refer to the “Contraindications” section in the specific type of transplant for more information.

- **Infections**
  - Systemic or uncontrolled infection including sepsis
- **Significant uncorrectable life-limiting medical conditions**
- **Severe end stage organ damage that would have an impact on patient survival**
- **Active untreated or untreatable malignancy**
- **Irreversible, severe brain damage**
- **Active alcohol dependency and substance abuse**
  - Active alcohol dependency and/or substance abuse requires six months of documented abstinence through participation in a structured alcohol/substance abuse program with regular meeting attendance and negative random drug testing. Active alcohol and substance abuse are defined as the consumption of alcohol in someone with a prior history of active alcohol dependency or the use of any illicit substance at any time in the six months prior to the request for transplant. **EXCEPTIONS:**

**FOR LIVER TRANSPLANTS:**

- Patient meets criteria for severe acute alcoholic hepatitis with documented failure of treatment and/or catastrophic decompensation where 6-months of abstinence is not realistic AND transplant center has an institutional protocol that requires, at a minimum:
  - Appropriate patient and psychosocial support profile. Transplant center must have an institutional protocol to conduct psychosocial evaluation and proactively implement interventions to promote post-transplant success.
  - Presence of close supportive social network
  - Absence of severe coexisting diseases or severe psychiatric disorders
  - Agreement by patient (with support of his/her social network) to post-transplant rehabilitation and monitoring, and to lifelong alcohol/cigarette abstinence
  - Evaluation by addiction specialist indicating high likelihood of success of post-transplant rehabilitation and abstinence
  - Approval by a medical review board that includes, in addition to the regular members, a psychiatrist, addiction specialist and an ethicist
  - No special consideration for acute decompensation with illicit drug addiction and/or abuse
  - Inactive alcohol and/or substance abuse (alcohol, crystal meth, heroin, cocaine, methadone, and/or narcotics, etc.)
  - Recreational or medicinal use of marijuana is not a contraindication.
FOR OTHER SOLID ORGAN TRANSPLANTS:

- Catastrophic decompensation where 6-months of abstinence is not realistic AND transplant center has an institutional protocol that requires, at a minimum:
  - Appropriate patient and psychosocial support profile. Transplant center must have an institutional protocol to conduct psychosocial evaluation and proactively implement interventions to promote post-transplant success.
  - Presence of close supportive social network
  - Absence of severe coexisting diseases or severe psychiatric disorders
  - Agreement by patient (with support of his/her social network) to post-transplant rehabilitation and monitoring, and to lifelong alcohol/cigarette abstinence
  - Evaluation by addiction specialist indicating high likelihood of success of post-transplant rehabilitation and abstinence
  - Approval by a medical review board that includes in addition to the regular members, a psychiatrist, addiction specialist and an ethicist
  - No special consideration for acute decompensation with illicit drug addiction and/or abuse
    - Inactive alcohol and/or substance abuse (alcohol, crystal meth, heroin, cocaine, methadone, and/or narcotics, etc.)
    - Recreational or medicinal use of marijuana is not a contraindication

References


Kidney including Kidney/Liver, Kidney/Heart & Kidney/Lung

General Information

- Kidney transplantation is the treatment of choice for suitable patients with end-stage kidney disease.
- Preemptive living donor transplantation is encouraged whenever possible.
- Candidates should be referred to a transplant center as soon as it appears probable that renal replacement therapy (dialysis) will be needed within the next 6–12 months. (Kasiske et al., 2001)
- Due to the very long wait times and the likely increased burden of comorbid conditions, patients over the age of 70 may not be considered for deceased donor transplantation by many kidney transplant programs. In many instances, while a member between 70–75 years of age may not be considered for a deceased donor transplant, a center may be willing to evaluate an older patient for a living donor transplant.
  - The importance of living donation in this situation should be emphasized with the patient
- Wait times in many parts of the country can last for years, particularly for those with blood groups O and B and those who are highly sensitized. Strategies to increase the likelihood of getting an organ include:
  - Patients should be very strongly encouraged to consider living donation and to seek out potential donors. Kidney Paired Donation/Exchange (KPD) is considered medically necessary.
  - Double listing in another United Network for Organ Sharing (UNOS) Region with a shorter wait time should be discussed and encouraged if the patient’s living situation will allow the flexibility to do this
  - ABO incompatible transplants are considered medically necessary
  - Desensitization protocols for highly sensitized (high PRA) patients are considered medically necessary
- Candidates should be informed that placement on the cadaveric waiting list does not guarantee transplantation, since changes in their medical status may delay or preclude transplantation. (Kasiske et al., 2001)
  - If a patient will have to be on a waiting list for a long time, the importance of maintaining transplant readiness by strict adherence to all advice from the transplant center, the treating nephrologist and the dialysis center should be emphasized
- Patients with primary oxalosis with ESRD should be considered for combined liver/kidney transplant (Eason et al., 2008; Compagnon et al., 2014).
Indications

- When to refer (Bunnapradist & Danovitch, 2007)
  - Kidney transplantation should be discussed with all patients with irreversible advanced chronic kidney disease (CKD)
  - Patients with CKD without known contraindications for transplantation should be referred to a transplant program when they approach CKD stage 4 or a glomerular filtration rate (GFR) less than 30 ml/min/1.73 m²
  - Early referral will improve the chances of a patient receiving a preemptive transplant, especially those with a potential living donor; referral to a kidney transplant program does not imply immediate transplantation

- End-stage renal disease (ESRD).
  - Chronic renal failure with glomerular filtration rate (GFR) < 20ml/min
  - Chronic renal failure on dialysis.
  - Symptomatic uremia

- Anticipated ESRD as defined above within next 12 months (preemptive transplantation).

- Combined kidney/liver transplant when at least one of the following are present: (OPTN Policy 9.9 Liver-Kidney Allocation; Table 9-17 Medical Eligibility Criteria for Liver-Kidney Allocation). See Appendix for National Kidney Foundation (NKF) definition of chronic kidney disease (CKD).
  - Candidates with sustained acute kidney injury (AKI)
    - Dialysis at least once every 7 days for the last 6 weeks AND/OR
    - eGFR ≤ 25 mL/min at least once every 7 days for the last 6 weeks
  - Candidates with chronic kidney disease (CKD) as defined by the National Kidney Foundation (NKF) AND at least one of the following:
    - Regularly administered dialysis as an end-stage renal disease (ESRD) patient in a hospital based, independent non-hospital based, or home setting.
    - eGFR ≤ 30 mL/min at time of listing.
  - Candidates diagnosed with at least one of the following:
    - Hyperoxaluria
    - Atypical hemolytic uremic syndrome (HUS) from mutations in factor H or factor I
    - Familial non-neuropathic systemic amyloidosis
    - Methylmalonic aciduria

- Combined heart/kidney transplant. (Russo et al., 2009; Hong et al., 2016; Gill et al., 2009)
  - Low risk patients with ESRD or CKD with eGFR < 33 ml/min. Refer to Medical Director.
• Retransplantation. Usually due to primary non-function, rejection, recurrent disease and/or immunosuppression toxicity.

Organ-specific Contraindications

Please review the Universal Contraindications found at the beginning of the Guidelines. These apply to all transplants unless otherwise noted below. Additional contraindications that are specific to a particular type of transplant are noted below. When a contraindication is present, the transplant will not be approved. Refer to the Medical Director.

• Reversible renal failure (Bunnapradist & Danovitch, 2007)

Special Considerations

Additional consultation and/or evaluation may be indicated in these situations. Refer to Medical Director if questions remain.

These recommendations are consistent with the 2001 American Society of Transplantation (AST) Clinical Practice Guidelines. (Kasiske et al., 2001)

• Requests for liver/kidney and kidney/heart transplants: Refer to Medical Director.

• Patients with a history of malignancy require an oncology evaluation to determine status of disease.

• Social and psychiatric issues can have significant impact on the outcomes of a transplant. It is expected that a psychosocial evaluation and/or a psychiatry consultation is obtained as part of the standard transplant evaluation. (Crone et al., 2010). The evaluation should address the following:
  - Overall functioning
  - Understanding of underlying illness and need for proposed treatment
  - History of adherence and compliance and barriers to compliance
  - Quality of relationships
  - Presence of a supportive caregiver
  - Social history including educational level and employment history
  - Housing and living situation including reliable transportation to attend medical visits
  - Socioeconomic status including sufficient funding to pay for immunosuppressive medications post-transplant
  - Current and past history of alcohol and substance use and abuse
  - Current and past psychiatric history including baseline cognitive status and coping skills

• Patients with human immunodeficiency virus (HIV) infection must be on a highly active antiretroviral therapy (HAART) regimen and there must be documented evidence of sustained viral load suppression.

• BMI ≥ 35 kg/m². NOTE: There are few data to suggest which, if any, obese patients should be denied transplantation based on obesity. (Kasiske et al., 2001)
  - Refer to requesting program Patient Selection Criteria.
  - If outside the program’s patient selection criteria, refer to Medical Director.
- Pediatric patients should have a normal history and physical, or if there is any indication of abnormal cardiac function, cardiology evaluation should be obtained.

- Adult patients with known heart disease including, but not limited to, heart failure, cardiomyopathy and coronary artery disease require cardiology consultation and completion of consultant’s recommendations, if any.

- Gastrointestinal (GI) clearance may be indicated in patients with a history of complicated or active GI disorders.

- Significant, uncorrectable pulmonary disease. Pulmonary consultation and completion of consultant’s recommendations, if any, is required.

References


Liver

General Information

Patients may be placed on the UNOS waiting list for a variety of reasons; hence, the overall clinical status will determine the need for listing. However, priority status is currently defined by the MELD score for adult recipients and the Pediatric End-Stage Liver Disease (PELD) score for pediatric recipients. PELD score is not required for listing but may be used for the purpose of assigning priority for organ allocation. Definitions and calculators for the MELD and PELD scores can be found on the OPTN website at: https://optn.transplant.hrsa.gov/resources/allocation-calculators/

- Adults with hepatocellular carcinoma (HCC) who meet Milan criteria (Mazzaferro, 1996) will be awarded MELD exception points. OPTN Dynamic Imaging criteria apply. See “Special Considerations” below.
  - Milan Criteria (Mazzaferro, 1996)
    - Not a candidate for subtotal hepatic resection.
    - Tumor is HCC stage II (T2 one nodule 2.0 – 5.0 cm; two or three nodules, all < 3.0 cm).
    - No macrovascular involvement.
    - No identifiable extrahepatic spread of tumor to surrounding lymph nodes, lungs, abdominal organs or bone.
  - Tumors can be downstaged with hepatic artery chemoembolization (HACE or TACE) with or without radiofrequency ablation (RFA). If successfully downstaged to be within the Milan criteria, MELD exception points are not automatically assigned. All such candidates with HCC, including those with downsized tumors who’s original or presenting tumor was greater than a stage T2, must be referred to the applicable Regional Review Board (RRB) for prospective review in order to receive additional priority.

- Children with the following conditions will be awarded PELD exception points:
  - Hepatoblastoma
  - Urea cycle disorders and organic acidemia.
  - Combined liver/intestine transplant.

- Living Donor Liver Transplant (LDLT). See “Indications” below.
  - Results from A2ALL (Berg et al., 2011 Olthoff et al., 2015) study demonstrated significant survival advantage associated with receipt of LDLT in comparison to continued waiting for Deceased Donor Liver Transplant (DDLT) for candidates with low laboratory MELD scores.
  - Complications of cirrhosis with low MELD score should be considered for LDLT (Koffron et al., 2008).

- Patients with primary oxalosis with ESRD should be considered for combined liver/kidney transplant. (Eason et al., 2008; Compagnon et al., 2014).
Indications


- Liver transplant candidate consistent with Organ Procurement and Transplant Network (OPTN) guidelines.
  - Transplantation is indicated for patients with End-Stage Liver Disease (ESLD) with a life expectancy < 12-24 months OR who have developed life-threatening complications OR with severe liver-associated debility frequently associated with sustained portal hypertension.
    - Intractable ascites usually requiring frequent paracenteses
    - Recurring variceal bleeding not well controlled with surgical banding and medical therapy
    - Recurring spontaneous bacterial peritonitis (SBP)
    - Intractable hepatic encephalopathy
    - Severe thrombocytopenia with complications
    - Intractable pruritus
    - Muscle wasting due to liver disease with other systemic illnesses excluded
    - Debilitating fatigue due to liver disease with other systemic illnesses excluded
    - Intractable hyponatremia
    - Hepatic chylothorax

- Living donor liver transplant is a valid treatment option for patients with low MELD scores, especially in cases where a deceased donor offer is not likely to occur.

- Polycystic liver disease with massive enlargement leading to physical impairment.

- Hepatocellular carcinoma within Milan criteria determined by the OPTN Dynamic Imaging criteria and no CONTRAINDICATIONS.
  - Not a candidate for subtotal resection
  - The HCC meets the definition of a Stage T2 lesion(s) that include any of the following:
    - One lesion greater than or equal to 2 cm and less than or equal to 5 cm in size
    - Two or three lesions greater than or equal to 1 cm and less than or equal to 3 cm in size
  - Written documentation has been submitted with the request that the lesion meets the definition of OPTN Class 5B, 5T or a combination of 5A lesions that meets the definition of tumor Stage T2
  - No macrovascular involvement
  - No identifiable extrahepatic spread of tumor to surrounding lymph nodes, lungs, abdominal organs or bone
• Hepatocellular carcinoma that has been downstaged.
  – Note: Successful downstaging does not result in an automatic award of MELD exception points. The case must be referred to the Regional Review Board with a request for exception points.
  – The inclusion criteria for downstaging should be a single tumor < 8 cm or 2 to 3 tumors, each < 5 cm, with a total tumor diameter < 8 cm and no vascular invasion by imaging criteria
  – The tumor must meet the Milan Criteria after the downstaging procedure.
  – Successful downstaging also requires a significant decrease in the AFP level to < 500 ng/ml for those patients with an initial AFP level > 1000 ng/ml. If post treatment AFP remains > 500 ng/ml, refer to medical director for review.

• Hepatocellular carcinoma that exceeds University of California, San Francisco (UCSF) criteria is a **CONTRAINDICATION** to transplantation:
  – Single lesion not exceeding 6.5 cm; OR
  – 2-3 lesions, none exceeding 4.5 cm, WITH
  – Total tumor diameter not greater than 8 cm.

• Cholangiocarcinoma (Martin et al., 2014) Refer to Medical Director with protocol.
  – May be approved under certain circumstances under the appropriate protocol at a center with an approved living donor liver transplant program OR a program in a region where the RRB will award MELD exception points to patients who qualify under the requesting program’s treatment protocol (Heimbach et al., 2006; Becker et al., 2008; and Gores, 2006)
  – If donor availability (living or deceased) is in doubt due to program qualification (living donor) or RRB policy (deceased donor), the member can be educated about other available in-network programs that can satisfy one or both donor requirements.

• Neuroendocrine tumors (NET). CMS has concluded: “It is unclear which patients could benefit in this rare disease, but some patients do appear to benefit from a transplant. Therefore, coverage of this treatment may be best considered only in carefully selected patients on a case by case basis at this time.” Refer to Medical Director. (Martin et al., 2014)

• Hemangioendothelioma (HAE). CMS and AASLD have concluded that generally patients with HAE have a better prognosis than do patients with HCC and may not have evidence of significant underlying liver disease. Consequently, transplantation is not common, but not necessarily contraindicated. For patients with large tumors liver transplantation should be considered for patients with unresectable HAE. Refer to Medical Director. (Martin et al., 2014)

• Hepatoblastoma: Children with hepatoblastoma may be considered for transplantation. The patient will have received multidisciplinary tumor board review and appropriate consideration of chemotherapy. PELD rules are not applied for patient selection.
  – If extrahepatic disease is not resectable or the patient is not a transplant candidate, additional chemotherapy, TACE, or radiation therapy may be indicated
• Retransplantation is usually due to primary non-function, hepatic artery thrombosis, portal vein thrombosis, rejection, chronic cholestasis without chronic rejection and recurrent disease.

Special Considerations

Additional consultation and/or evaluation may be indicated in these situations. Refer to Medical Director if questions remain.

Unless otherwise annotated, these recommendations are consistent with the 2013 American Association for the Study of Liver Disease (AASLD) Clinical Practice Guidelines. (Martin et al., 2014)

• Refer the following requests for transplant to the Medical Director:
  – Combined heart/liver
  – Combined liver/lung
  – Combined liver/kidney that do not meet the OPTN requirements as outlined on page 8 of this guideline

• Additional considerations may be present where liver transplantation may be appropriate in other circumstances where quality of life considerations become paramount.
  – Conditions eligible for MELD exception points:
    • Cystic fibrosis with signs of reduced pulmonary function with forced expiratory volume at one second (FEV₁) that falls below 40 percent
    • Portopulmonary hypertension
    • Hepatic artery thrombosis within 14 days of transplant
    • Hepatoblastoma (pediatric) eligible for PELD exception points
    • Urea cycle disorder or organic acidemia (pediatric) eligible for PELD exception points
    • Primary oxaluria eligible for MELD exception points
    • Hepatopulmonary syndrome eligible for MELD exception points
    • Combined liver/intestine or multivisceral transplant
    • Familial amyloidosis/familial amyloid polyneuropathy (FAP)
      – Patients may have no measurable abnormality of liver function at the time of the request for authorization
      – Liver transplants generally are done below the age of 30 AND when the patients are clinically well
      – Patients may be living donors for a domino transplant
    – All other presentations not eligible for automatic MELD exception points including but not limited to intractable pruritus (itching), recurrent spontaneous bacterial peritonitis, bleeding, ascites, thrombocytopenia, encephalopathy, polycystic liver disease or other quality of life issues not adequately accounted for in the MELD/PELD score may be considered. Refer to Medical Director.
Social and psychiatric issues can have significant impact on the outcomes of a transplant. It is expected that a psychosocial evaluation and/or a psychiatry consultation is obtained as part of the standard transplant evaluation. (Crone et al., 2020). The evaluation should address the following:

- Overall functioning
- Understanding of underlying illness and need for proposed treatment
- History of adherence and compliance and barriers to compliance
- Quality of relationships
- Presence of a supportive caregiver
- Social history including educational level and employment history
- Housing and living situation including reliable transportation to attend medical visits
- Socioeconomic status including sufficient funding to pay for immunosuppressive medications post-transplant
- Current and past history of alcohol and substance use and abuse
- Current and past psychiatric history including baseline cognitive status and coping skills

Patients with a history of malignancy require an oncology evaluation to determine status of disease.

Patients with human immunodeficiency virus (HIV) infection must be on a highly active antiretroviral therapy (HAART) regimen and there must be documented evidence of sustained viral load suppression.

BMI ≥ 35 kg/m²
- Refer to requesting program Patient Selection Criteria
- If outside the program’s patient selection criteria, refer to Medical Director

Pediatric patients should have a normal history and physical, or if there is any indication of abnormal cardiac function, cardiology evaluation should be obtained.

Adult patients with known heart disease including but not limited to heart failure, cardiomyopathy and coronary artery disease require cardiology consultation and completion of consultant’s recommendations if any.

Significant, uncorrectable pulmonary disease. Pulmonary consultation and completion of consultant’s recommendations if any is required.

Gastrointestinal clearance may be indicated in patients with a history of complicated or active GI disorders.

References


Pancreas & Kidney/Pancreas

General Information

- There are three variations of pancreas and kidney/pancreas transplants.
  - Both organs can be implanted during one procedure and this is referred to as simultaneous pancreas kidney transplantation (SPK)
  - The pancreas can be transplanted after a kidney transplant and this is referred to as pancreas after kidney transplantation (PAK)
  - The pancreas can be transplanted alone and this is called pancreas transplant alone (PTA)

- SPK, PAK or PTA may be indicated in patients with either Type 1 or Type 2 diabetes. Pancreas transplantation can provide excellent outcomes for patients with labile diabetes (Gruessner, 2011). The outcomes of combined kidney pancreas transplants in Type 2 diabetics are comparable to the outcomes in Type 1 diabetics. (Light et al., 2006; Nath et al., 2005)

- SPK transplant is the definitive treatment of Type 1 diabetes combined with end-stage renal disease. Long-term graft function can lead to improvement in diabetes-related complications and, in patients younger than 50 years, can lead to improved overall survival. PAK transplant and PA transplant do not result in similar improvements in patient survival, but with appropriate patient selection, they can improve quality of life by rendering patients insulin-free. (Dhanireddy, 2012)

- A pancreas transplant may be justified on the basis that patients replace daily injections of insulin with an improved quality of life but at the expense of a major surgical procedure and lifelong immunosuppression. (White, 2009)

- The rates of patient survival are approximately 97% at 1 year and 92% at 3 years after SPK transplantation. Similar patient survival rates are reported for PAK and PTA recipients. Graft survival is variable, depending on the type of pancreas transplant performed. The mortality among diabetics is greatly reduced by SPK transplantation compared with the waiting list; however, it is less so for solitary pancreas transplants. (Redfield et al., 2016)

- Complications include graft thrombosis, bleeding, abdominal abscess, pancreatic leak, urinary tract infection, and early rejection. (Ablorsu, 2008) Pancreas transplant is associated with more surgical complications and higher perioperative morbidity and mortality than kidney transplant alone. (Dhanireddy, 2012) There is a high incidence of kidney graft failure in SPK recipients, following a pancreas graft loss. About 50% of the kidney graft failure occurred within three months after the loss of the pancreas graft. (Hill, 2008)

- Allogeneic Islet Cell transplantation is an experimental procedure and IS NOT covered except:
  - When performed under a clinical trial AND
  - A clinical trial benefit exists AND
  - The trial conforms to the provisions of that benefit.
• Autologous islet cell transplantation following total pancreatectomy for non-malignant conditions is an accepted treatment to prevent the immediate onset of insulin dependent diabetes mellitus. (Bramis, 2012) This is a covered MEDICAL benefit under the UHC COC. Autologous islet cell transplant is not a true transplant procedure. Rather, it involves the infusion of the patient’s own islet cells into his/her liver where they will independently produce insulin.

NOTE: For Optum nurses, autologous islet cell transplant is covered under the member’s medical benefit. Refer to Job Aid 9996637: TS Auto Islet Cell Transplant Notification NF/EC Process.

– Isolating the islets from an excised pancreas must be done by an experienced laboratory and the centers performing these infusions must have extensive experience with autologous islet cell infusions and patient management post-infusion.
– Reinfusion of the islets does not prevent the pancreatic exocrine insufficiency that follows total pancreatectomy. This is managed in the same way as for any patient who has undergone a total pancreatectomy.
– Post-infusion management of these patients is the same as the management of any other patient at risk for the development of diabetes.
– Autologous islet cell transplantation is a laboratory and procedural add-on to the cost of a total pancreatectomy. It should not be considered an organ transplant.
– Most patients will develop diabetes eventually. (Dean et al., 2008) Even though the islets lodge in the liver and function normally initially, this is not a normal environment for them. The pancreas they were taken from was not normal. Because of the underlying pancreatic disease and normal loss in processing, the number and quality of islets is not normal. The reinfused islets will eventually stop functioning. But, for the time that they are functioning, the patient is protected against the immediate development of diabetes following a total pancreatectomy. However, concurrent IAT enabled a significant proportion of patients to remain independent of insulin supplementation. (Bramis, 2012)

Indications

• SPK and PAK:
  – Qualifies for kidney transplant (see KIDNEY) AND the member is diabetic. The outcomes of combined kidney pancreas transplants in Type 2 diabetics are comparable to the outcomes in Type 1 diabetics. (Light & Barhyte, 2006)
    • The criteria for covering a pancreas transplant alone are not applicable when a kidney is also being transplanted

• PTA:
  – Type 1 diabetes mellitus with one or both of the following:
    • Labile diabetes mellitus with documented life-threatening hypoglycemic unawareness and/or frequent hypoglycemic episodes despite optimal medical management, Clarke Hypoglycemic Score ≥ 4 (Geddes et al., 2007) AND/OR
• Inability to tolerate exogenous insulin.
  – Type 2 diabetes mellitus meeting the following criteria with one of the following:
    • Labile diabetes mellitus with documented life-threatening hypoglycemic unawareness
despite optimal medical management, Clarke Hypoglycemia Score $\geq 4$ OR
    • Severe physical or psychological impairment that make it impossible to administer
exogenous insulin safely.
  – Appropriate candidates will have all of the following characteristics: (Stratta, 2009)
    • Insulin requiring diabetes for > 5 years receiving $\leq 1$ unit/kg/day
    • BMI $\leq 30$
    • Age $< 60$
    • No history of major vascular events such as bilateral limb amputations and disabling CVA
    • Not actively smoking
    • Left ventricular ejection fraction $\geq 40\%$ with no left ventricular hypertrophy

• Retransplantation is usually due to non-function of the grafted organ(s), chronic rejection and
chronic allograft pancreatitis.

**Organ-specific Contraindications**

*Please review the Universal Contraindications found at the beginning of the Guidelines. These apply to all transplants unless otherwise noted below. Additional contraindications that are specific to a particular type of transplant are noted below. When a Contraindication is present the transplant will not be approved. Refer to the Medical Director.*

• Significant cardiac disease: (Stratta, 2009)
  – Non-correctable coronary artery disease
  – Ejection fraction (LVEF, EF) $< 40\%$

**Special Considerations**

*Additional consultation and/or evaluation may be indicated in these situations. Refer to Medical Director if questions remain.*

• Serum C-peptide.
  – Serum C-peptide measurements are not required. Transplant candidacy is based on other
considerations noted elsewhere in this document. (Stratta, 2009)

• Autologous Islet Cell transplantation. (Bramis, 2012)
  – May be indicated following total pancreatectomy for non-malignant conditions.
  – Check benefits to determine if it is covered under a particular plan.
NOTE: For Optum nurses, autologous islet cell transplant is covered under the member’s medical benefit. Refer to Job Aid 22211095: TS Auto Islet Cell Transplant Notification NF/EC Process.

- Social and psychiatric issues can have significant impact on the outcomes of a transplant. It is expected that a psychosocial evaluation and/or a psychiatry consultation is obtained as part of the standard transplant evaluation. (Crone et al., 2020). The evaluation should address the following:
  - Overall functioning
  - Understanding of underlying illness and need for proposed treatment
  - History of adherence and compliance and barriers to compliance
  - Quality of relationships
  - Presence of a supportive caregiver
  - Social history including educational level and employment history
  - Housing and living situation including reliable transportation to attend medical visits
  - Socioeconomic status including sufficient funding to pay for immunosuppressive medications post-transplant
  - Current and past history of alcohol and substance use and abuse
  - Current and past psychiatric history including baseline cognitive status and coping skills

- Patients with a history of malignancy require an oncology evaluation to determine status of disease.

- Patients with human immunodeficiency virus (HIV) infection must be on a highly active antiretroviral therapy (HAART) regimen and there must be documented evidence of sustained viral load suppression.

- BMI $\geq$ 35 kg/m$^2$.
  - Refer to requesting program Patient Selection Criteria.
  - If outside the program’s patient selection criteria, refer to Medical Director.

- Pediatric patients should have a normal history and physical, or if there is any indication of abnormal cardiac function, cardiology evaluation should be obtained.

- Adult patients with known heart disease including but not limited to heart failure, cardiomyopathy and coronary artery disease require cardiology consultation and completion of consultant’s recommendations, if any.

- Gastrointestinal clearance may be indicated in patients with a history of complicated or active GI disorders

- Patients over the age of 60. (Ablorsu, 2008)
  - Refer to requesting program Patient Selection Criteria.
  - If outside the program’s patient selection criteria, refer to Medical Director.

- Significant, uncorrectable pulmonary disease. Pulmonary consultation and completion of consultant’s recommendations if any is required.
Clarke Hypoglycemic Score

1. Check the category that best describes you: (check only one)
   - I always have symptoms when my blood sugar is low (A)
   - I sometimes have symptoms when my blood sugar is low (R)
   - I no longer have symptoms when my blood sugar is low (R)

2. Have you lost some of the symptoms you used to have when your blood sugar was low?
   - Yes (R)
   - No (A)

3. In the past six months how often have you had moderate hypoglycemia episodes? (Episodes where you might feel confused, disoriented, or lethargic and were unable to treat yourself)
   - Never (A)
   - Once or twice (R)
   - Every other month (R)
   - Once a month (R)
   - More than once a month (R)

4. In the past year how often have you had severe hypoglycemic episodes? (Episodes where you were unconscious or had seizure and needed glucagon or intravenous glucose)
   - Never (A)
   - 1 time (R)
   - 2 times (R)
   - 3 times (R)
   - 5 times (R)
   - 6 times (R)
   - 7 times (R)
   - 8 times (R)
   - 9 times (R)
   - 10 times (R)
   - 11 times (R)
5. How often in the last month have you had readings < 70 mg/dl with symptoms?
   - Never
   - 1 to 3 times
   - 1 time/week
   - 2 to 3 times/week
   - 4 to 5 times/week
   - Almost daily

6. How often in the last month have you had readings < 70 mg/dl without any symptoms?
   - Never
   - 1 to 3 times
   - 1 time/week
   - 2 to 3 times/week
   - 4 to 5 times/week
   - Almost daily

   (R = answer to 5 < answer to 6, A = answer to 6 > answer to 5)

7. How low does your blood sugar need to go before you feel symptoms?
   - 60 – 69 mg/dl (A)
   - 50 – 59 mg/dl (A)
   - 40 – 49 mg/dl (R)
   - < 40 mg/dl (R)

8. To what extent can you tell by your symptoms that your blood sugar is low?
   - Never (R)
   - Rarely (R)
   - Sometimes (R)
   - Often (A)
   - Always (A)

Hypoglycemic unawareness (Clarke score): R ≥ 4
References


Intestine including Liver/Intestine & Multivisceral

General Information

- Patients with intestinal failure syndromes should be managed in centers with robust intestinal failure/rehabilitation programs to take advantage of all opportunities to regain adequate function and to avoid total parenteral nutrition (TPN) with its complications and intestinal transplant. (Beathe et al., 2008; Torres et al., 2007) If no evaluation for intestinal rehabilitation has been performed, the member may be redirected to a program that has the capacity to perform these important evaluation and management services.

- Adaptation following disease or injury that leads to intestinal failure can occur over many months up to a year or more. The ability of the remaining gut to adapt to be able to support the patient with enteral nutrition alone is determined by a number of factors including the length of the remaining intestine, the segments remaining, the presence of an ileocecal valve, the presence or absence of the colon and general motility patterns. A number of medical and surgical interventions are possible to help many of these patients avoid transplant. (Centers for Medicare and Medicaid; Fryer, 2007)

- Timelier referral of intestinal failure patients who have not yet developed end-stage liver disease may allow for an intestine only transplant (IOT), which is associated with better outcomes. (Chungfat et al., 2007)

- The short-term survival of pediatric intestine recipients has significantly improved in the last decade and reached 90% at the end of the first year after transplant in high-volume intestinal transplant centers. (Avitzur & Grant, 2010)

Indications

- Intestine
  - Patients with irreversible intestinal failure with associated life-threatening complications (Fishbein, 2009)
  - Patients with secretory diarrhea of childhood may have high mortality/morbidity due to their underlying disease and therefore can be considered for intestine transplant evaluation in the absence of life-threatening complications. (Ruemmele et al., 2004)
  - Dependent on TPN with cholestatic liver disease as defined by elevated direct bilirubin. If cholestasis is advanced, or cirrhosis is present, a combined liver/intestine transplant may be considered. (Colomb et al., 2007)
  - Isolated intestinal transplants are performed in the presence of cholestasis only when the liver disease is felt to be reversible
  - Inability to maintain fluid and electrolyte balance
  - Recurrent sepsis as a result of either line sepsis or intestinal stasis
  - Dependent on TPN with loss of or impending loss of (using last major vessel) vascular access
  - Non-reconstructible gastrointestinal (GI) tract
Intestine including Liver/Intestine & Multivisceral

• Liver/small bowel/pancreas with or without addition of stomach or colon
  – Liver/intestine
    • One of the above AND
    • Biopsy proven fibrotic changes within the liver indicating that the TPN associated liver dysfunction is irreversible OR
    • Clinical assessment of significant portal hypertension (such as hypersplenism) where biopsy may not be available or warranted or considered safe to perform
  – Multivisceral
    • All the above under Intestine AND
    • Technical considerations that make the anastomoses of one or more of the separate organs problematic when compared to an en bloc dissection and transplantation that requires fewer vascular and intestinal anastomoses OR
    • Desmoid tumors OR
    • Severe gastric or antroduodenal motility disorder (pseudo-obstruction). (Cruz et al., 2010) OR
    • Patients listed for multivisceral transplantation without TPN dependency require special case review. (Kaufman et al., 2001)

Subsequent recovery of hyperbilirubinemia with nutritional and medical management may allow for “delisting” or consideration of isolated intestine transplant if the liver has improved despite initial biopsy findings.

• Retransplantation
  – May occur when there is a failed prior intestinal transplantation, including non-function of the grafted organ, acute rejection requiring enterectomy, or chronic rejection

Special Considerations

Additional consultation and/or evaluation may be indicated in these situations. Refer to Medical Director if questions remain.

• Social and psychiatric issues can have significant impact on the outcomes of a transplant. It is expected that a psychosocial evaluation and/or a psychiatry consultation is obtained as part of the standard transplant evaluation. (Crone et al., 2020). The evaluation should address the following:
  – Overall functioning
  – Understanding of underlying illness and need for proposed treatment
  – History of adherence and compliance and barriers to compliance
  – Quality of relationships
  – Presence of a supportive caregiver
  – Social history including educational level and employment history
  – Housing and living situation including reliable transportation to attend medical visits
- Socioeconomic status including sufficient funding to pay for immunosuppressive medications post-transplant
- Current and past history of alcohol and substance use and abuse
- Current and past psychiatric history including baseline cognitive status and coping skills.

- Patients with a history of malignancy require an oncology evaluation to determine status of disease.
- Patients with human immunodeficiency virus (HIV) infection must be on a highly active antiretroviral therapy (HAART) regimen and there must be documented evidence of sustained viral load suppression.
- BMI $\geq 35$ kg/m$^2$
  - Refer to requesting program Patient Selection Criteria
  - If outside the program’s patient selection criteria, refer to Medical Director
- Pediatric patients should have a normal history and physical, or if there is any indication of abnormal cardiac function, cardiology evaluation should be obtained.
- Adult patients with known heart disease including but not limited to heart failure, cardiomyopathy and coronary artery disease require cardiology consultation and completion of consultant’s recommendations, if any.
- Gastrointestinal clearance may be indicated in patients with a history of complicated or active GI disorders.
- Patients over the age of 60
  - Refer to requesting program Patient Selection Criteria.
  - If outside the program’s patient selection criteria, refer to Medical Director.
- Significant, uncorrectable pulmonary disease. Pulmonary consultation and completion of consultant’s recommendations if any is required.

References


Heart

General Information

- Cardiac transplantation is an option for patients with end-stage heart disease. About 2,000 heart transplants are performed each year in the United States. This number has remained relatively stable due to a lack of donors. The major indications for cardiac transplant were coronary artery disease and dilated cardiomyopathy, but over the past 20 years, dilated cardiomyopathy has supplanted coronary artery disease as the major cause. Survival rates have improved with the advent of newer immunosuppressive agents (tacrolimus and mycophenolate). The median survival for 43,906 heart transplants was approximately 9 years. At 20-years the survival rate continued to decline to reach < 10%. Seven-year survival rates for heart transplant recipients transplanted between 1998-1994, 1995-2000, and 2000-2007 were 59%, 62% and 65%, respectively. Infant heart recipients (less than one year old) had poor survival rates during the first post-transplant year (74% compared to > 85% for all other age groups), but those who survived had better long-term outcomes than adults. Elderly recipients (aged 65 or older) had survival rates comparable to younger patients through about 8 years, when survival rates began to fall more rapidly. In spite of these statistics, the long-term success of cardiac transplants still has room for improvement. (Everly, 2008)

- In prior guideline, Chagas disease was identified as a contraindication to heart transplantation. The International Society for Heart and Lung Transplantation (ISHLT) has since identified heart transplantation as an accepted treatment of choice for heart failure caused by Chagas disease, despite the risks of reactivation of Trypanosoma cruzi infection. (Mehra et al., 2016)

- Due to the limited availability of suitable hearts for transplant, mechanical support devices have been developed. These surgically implanted devices are intended as a bridge to transplantation (BTT) for heart-transplant-eligible candidates with nonreversible biventricular failure and who are at risk of imminent death and for destination therapy (DT) for those patients who are not eligible for heart transplant at the time of implantation.

- The proportion of patients receiving a heart transplant with a mechanical circulatory support device (MCSD) in place at the time of transplant has risen to 50.6% according to the July 2015 report from the Scientific Registry of Transplant recipients (SRTR). The majority of these devices are VADs. (Alba, 2010) See complete discussion below.

- Ventricular Assist Devices.


- SynCardia Total Artificial Heart.
  - A total artificial heart (TAH) can maintain the life of a patient with biventricular heart failure.
  - The SynCardia (formerly known as the CardioWest Total Artificial Heart (TAH) is available in 34 centers in the US with 13 more in the process of certification by the manufacturer as of July 22, 2012.
– The Freedom Driver is approved for use under a clinical trial in the United States. This allows patients with the TAH to be discharged home pretransplant for the first time. This device is used as BTT for patients with severe right heart failure in addition to left heart failure. A DT trial has recently been opened.

– The FDA has recently approved the use of the Total Artificial Heart for Destination Therapy under a Humanitarian Use Device Exception (HDE).

– Please refer to Total Artificial Heart Medical Policy available internally on Knowledge Library or externally at: https://www.unitedhealthcareonline.com/ccmcontent/ProviderII/UHC/en-US/Assets/ProviderStaticFiles/ProviderStaticFilesPdf/Tools%20and%20Resources/Policies%20and%20Protocols/Medical%20Policies/Medical%20Policies/Total_Artificial_Heart.pdf.

**Indications**

- Likelihood of death from heart disease within 12 - 24 months without transplant.
- Heart failure with severe cardiac disability despite optimal medical therapy, New York Heart Association Class III or IV or American Heart Association Stage D AND objective evidence of impaired functional capacity (peak oxygen consumption < 14 ml/kg/min). See Appendix for specific description of heart failure categories. (Acker & Jessup, 2011; Jessup et al., 2006; Canter, 2007)
- Valvular heart disease with left ventricular dysfunction (not correctable with valve replacement or repair).
- Recurrent life-threatening arrhythmias not otherwise correctable despite maximal antiarrhythmic and all appropriate conventional medical and surgical modalities (including implantable devices and multiple firings from an ICD for documented VT and VF). (Acker & Jessup, 2011)
- Intractable angina with coronary artery disease despite maximal medical therapy that is not amenable to revascularization. (Yamani & Taylor, 2010)
- Primary cardiac tumors confined to the myocardium, with a low likelihood of metastasis at time of transplantation. (Yamani & Taylor, 2010)
- Refractory heart failure requiring continuous inotropic (medications that support cardiac muscle contraction) support.
- Severe hypertrophic or restrictive cardiomyopathy, with NYHA Class IV symptoms. (Yamani & Taylor, 2010)
- Congenital Heart Disease (CHD) that is not amenable to surgical therapy or that has failed previous surgical correction. (Patel, 2009)
- Retransplantation due to primary graft failure, rejection refractory to immunosuppressive therapy and graft coronary artery disease with severe ischemia of the heart graft. Retransplantation appears most appropriate for those patients more than 6 months following original heart transplantation, who have severe cardiac allograft vasculopathy and associated left ventricular dysfunction, or allograft dysfunction and progressive symptoms of heart failure in the absence of acute rejection. (Johnson, 2007)
• Combined heart/kidney transplant. (Russo et al., 2009; Hong et al., 2016; Gill et al., 2009)
  – Low risk patients with ESRD or CKD with eGFR < 33 ml/min. Refer to Medical Director.

Organ-specific Contraindications

*Please review the universal Contraindications found at the beginning of the Guidelines. These apply to all transplants unless otherwise noted below. Additional contraindications that are specific to a particular type of transplant are noted below. When a Contraindication is present the transplant will not be approved. Refer to the Medical Director.*

Unless otherwise annotated, these recommendations are consistent with the 2016 International Society for Heart Lung Transplantation (ISHLT) Listing Criteria for Heart Transplantation: A 10-year update. (Mehra et al., 2016)

• Significant peripheral vascular disease not correctable with surgery

• Significant uncorrectable life-limiting medical conditions such as severe end stage organ damage including: Severe diabetes mellitus with end organ damage, irreversible severe pulmonary disease, with FEV₁ < 1 L or FVC < 50%, irreversible severe hepatic disease, irreversible severe renal disease etc. (Acker & Jessup, 2011)

• Active systemic and/or uncontrolled infection associated with left ventricular assist device.

• Ongoing tobacco use. (Acker & Jessup, 2011)

Special Considerations

*Additional consultation and/or evaluation may be indicated in these situations. Refer to Medical Director if questions remain.*

Unless otherwise annotated, these recommendations are consistent with the 2016 International Society for Heart Lung Transplantation (ISHLT) Listing Criteria for Heart Transplantation: A 10-year update. (Mehra et al., 2016)

• Severe irreversible pulmonary hypertension:
  – Pulmonary arterial systemic pressure > 60 mm Hg, mean transpulmonary gradient > 15 mm Hg, and/or pulmonary vascular resistance (PVR) > 5 Wood units on maximal vasodilator therapy. (Alba, 2010) However, the patient may qualify for combined heart/lung transplantation.

  – Elevated PVR defined as a PVR > 5 Woods units, a PVR index > 6, or a transpulmonary pressure gradient 16 to 20 mmHg, should be considered as relative contraindications to isolated cardiac transplantation. If the pulmonary artery systolic pressure is > 60 mmHg in conjunction with any of these 3 variables, the risk of right heart failure and early death is increased. If the PVR can be reduced to < 2.5 with a vasodilator but the systolic blood pressure falls to < 85 mmHg, the patient remains at high risk of right heart failure and mortality after isolated cardiac transplantation. (Weill et al., 2015)
The current recommended practice is to perform right heart catheterization, treat with vasodilator, intraaortic balloon pump (IABP) and/or mechanical circulatory support device and follow with serial right heart catheterization. If the PA pressure and PVR do not respond to these interventions after 3 to 6 months it is reasonable to conclude that pulmonary artery hypertension is irreversible. (Mehra et al., 2016)

Refer to program patient selection criteria

- Primary non-function or less than one year since the initial transplant. For Optum case managers: file Quality of Care concern through COMPASS Issues Management/Submit a member complaint/Complex Medical Conditions and inform Medical Director. http://optumcrt.uhc.com/sites/issuesmgmt/Pages/SubmitMCC.aspx.

- Patients with renal failure can be evaluated for combined heart-kidney transplantation.

  - Requests for heart/liver and kidney/heart transplants: Refer to Medical Director.

- Significant chronic pulmonary disease defined as FVC < 50%, non-reversible FEV1 < 50 % and DLCO (corrected) < 40 % for adults (< 50 % in children).

  - Pulmonary clearance required

- Diabetes with end-organ damage other than nonproliferative retinopathy or poor glycemic control (HgbA1C > 7.5 or 55 mmol/mol) despite optimal effort is a relative contraindication for transplant.

- Patients with a history of malignancy require an oncology evaluation to determine status of disease.

- Social and psychiatric issues can have significant impact on the outcomes of a transplant. It is expected that a psychosocial evaluation and/or a psychiatry consultation is obtained as part of the standard transplant evaluation. (Crone et al., 2020). The evaluation should address the following:

  - Overall functioning
  - Understanding of underlying illness and need for proposed treatment
  - History of adherence and compliance and barriers to compliance
  - Quality of relationships
  - Presence of a supportive caregiver
  - Social history including educational level and employment history
  - Housing and living situation including reliable transportation to attend medical visits
  - Socioeconomic status including sufficient funding to pay for immunosuppressive medications post-transplant
  - Current and past history of alcohol and substance use and abuse
  - Current and past psychiatric history including baseline cognitive status and coping skills

- BMI > 35 kg/m².

  - Refer to requesting program Patient Selection Criteria.

  - If outside the program’s patient selection criteria, refer to Medical Director.

- Patients over the age of 70.

  - Refer to requesting program Patient Selection Criteria.
- If outside the program’s patient selection criteria, refer to Medical Director.

- Patients with human immunodeficiency virus (HIV) infection must be on a highly active antiretroviral therapy (HAART) regimen and there must be documented evidence of sustained viral load suppression.

- Gastrointestinal (GI) clearance may be indicated in patients with a history of complicated or active GI disorders.

- Recent stroke - unless associated with left ventricular assist device. (Jessup et al., 2006)

- Active pulmonary embolism (< 6 weeks). (Jessup et al., 2006)

**New York Heart Association (NYHA) Functional Classification**

<table>
<thead>
<tr>
<th>Class</th>
<th>Patient Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I</td>
<td>No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation (feeling heart beats), dyspnea (shortness of breath) or anginal pain.</td>
</tr>
<tr>
<td>Class II</td>
<td>(Mild) - Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, dyspnea or anginal pain.</td>
</tr>
<tr>
<td>Class III</td>
<td>(Moderate) - Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, dyspnea or anginal pain.</td>
</tr>
<tr>
<td>Class IV</td>
<td>(Severe) - Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency or the anginal syndrome may be present at rest. If any physical activity is undertaken, discomfort is increased.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Class</th>
<th>Objective Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>No objective evidence of cardiovascular disease. No symptoms and no limitation in ordinary physical activity.</td>
</tr>
<tr>
<td>C</td>
<td>Objective evidence of moderately severe cardiovascular disease. Marked limitation in activity due to symptoms, even during less-than-ordinary activity. Comfortable only at rest</td>
</tr>
<tr>
<td>D</td>
<td>Objective evidence of severe cardiovascular disease. Severe limitations. Experiences symptoms even while at rest.</td>
</tr>
</tbody>
</table>
# American Heart Association Classification (AHA)

<table>
<thead>
<tr>
<th>Stage</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage A</td>
<td>Presence of heart failure risk factors but no heart disease and no symptoms</td>
</tr>
<tr>
<td>Stage B</td>
<td>Heart disease is present but there are no symptoms (structural changes in heart before symptoms occur)</td>
</tr>
<tr>
<td>Stage C</td>
<td>Structural heart disease is present AND symptoms have occurred</td>
</tr>
<tr>
<td>Stage D</td>
<td>Presence of advanced heart disease with continued heart failure symptoms requiring aggressive medical therapy</td>
</tr>
</tbody>
</table>
References


Canter CE. Indications for heart transplantation in pediatric heart disease: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young; the Councils on Clinical Cardiology, Cardiovascular Nursing, and Cardiovascular Surgery and Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. *Circulation*. 2007 Feb;115(5):658-76.


NYHF. Accessed July 20, 2012. Available at: http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-Heart-Failure_UCM_306328_Article.jsp.


Lung

General Information

- The indications for lung transplantation include a diverse array of pulmonary diseases of the airways, parenchyma, and vasculature.

- From the International Society for Heart and Lung Transplantation (ISHLT) Consensus Document for the Selection of Lung Transplant Candidates: 2014 — An Update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation (Weill et al.): “Lung transplant should be considered for adults with chronic, end-stage lung disease who meet all of the following criteria: High (50%) risk of death from lung disease within 2 years if lung transplantation is not performed; High (80%) likelihood of surviving at least 90 days after lung transplantation; and High (80%) likelihood of 5-year post-transplant survival from a general medical perspective provided that there is adequate graft function.”

- The patient selection criteria, timing of listing and choice of procedure type are critically important steps in optimizing the outcome of lung transplantation.

- In general, referral for transplantation assessment is advisable when patients have a less than 50%, 2 to 3 year predicted survival or New York Heart Association (NYHA) class III or IV level of function, or both. (Orens et al., 2006)

- The Lung Allocation Score (LAS) is used to place patients on the lung wait list. This is similar to the MELD system for liver transplantation. The LAS takes into account the severity of the illness pre-transplant including the likelihood of death on the waiting list and the likelihood of survival one-year post-transplant. The LAS is a dynamic measurement that is updated on a regular basis according to a follow-up schedule determined by UNOS. Waiting time on the list is no longer an important criterion. Information about the LAS and the LAS Calculator can be found at: https://optn.transplant.hrsa.gov/resources/allocation-calculators/las-calculator/

- Unique to lung transplantation, decisions must often be made about whether to replace one or both lungs. (Kreider, 2009) The choice of single or double lung transplantation is a clinical decision that is left to the treating physicians.

- Double lung transplantation is indicated for cystic fibrosis and other lung diseases characterized or complicated by chronic infections.

Indications

- Any ambulatory patient with end-stage pulmonary disease.
  - Clinically and physiologically severe disease
  - Medical therapy ineffective or unavailable
  - Limited life expectancy, usually less than two to three years
  - Ambulatory, with rehabilitation potential
  - Acceptable nutritional status, usually 80 – 120 % of ideal body weight
  - Satisfactory psychosocial profile and support system
- Adequate coverage for the procedure and for post-transplantation care
- Age < 65 or in well selected patients with end-stage pulmonary disease who are > 65 years old (Machuca, 2011)

- Typical patient selection criteria are recommended in peer reviewed medical literature and many of which are taken into considered in the LAS.

- Retransplantation is usually due to non-function of the grafted organ, rejection refractory to immunosuppressive therapy, bronchiolitis obliterans (chronic rejection) and airway complications not correctable by other measures.

**Organ-specific Contraindications**

*Please review the universal Contraindications found at the beginning of the Guidelines. These apply to all transplants unless otherwise noted below. Additional contraindications that are specific to a particular type of transplant are noted below. When a contraindication is present the transplant will not be approved. Refer to the Medical Director.*

Unless otherwise annotated, these recommendations are consistent with the International Society for Heart and Lung Transplantation (ISHLT) Consensus Document for the Selection of Lung Transplant Candidates: 2014 — An Update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. (Weill et al., 2015)

- Significant chest wall/spinal deformity. (Moreno, 2008)

- Active or recent history of smoking including tobacco or marijuana. Requires 6 months of documented abstinence through participation in a structured smoking cessation program and, in the case of marijuana, participation in a substance abuse program with regular meeting attendance and negative random drug testing. This may be part of an overall smoking cessation program for those who use both tobacco and marijuana.

**Special Considerations**

*Additional consultation and/or evaluation may be indicated in these situations. Refer to Medical Director if questions remain.*

Unless otherwise annotated, these recommendations are consistent with the International Society for Heart and Lung Transplantation (ISHLT) Consensus Document for the Selection of Lung Transplant Candidates: 2014 — An Update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. (Weill et al., 2015)

- Primary non-function or less than one year since the initial transplant. For Optum case managers: file Quality of Care concern through COMPASS Issues Management/Submit a member complaint/Complex Medical Conditions and inform Medical Director. [http://optumcrt.uhc.com/sites/issuesmgmt/Pages/SubmitMCC.aspx](http://optumcrt.uhc.com/sites/issuesmgmt/Pages/SubmitMCC.aspx).

- Patients with a history of malignancy require an oncology evaluation to determine status of disease.

- Social and psychiatric issues can have significant impact on the outcomes of a transplant. It is expected that a psychosocial evaluation and/or a psychiatry consultation is obtained as part of the standard transplant evaluation. (Crone et al., 2020). The evaluation should address the following:
- Overall functioning
- Understanding of underlying illness and need for proposed treatment
- History of adherence and compliance and barriers to compliance
- Quality of relationships
- Presence of a supportive caregiver
- Social history including educational level and employment history
- Housing and living situation including reliable transportation to attend medical visits
- Socioeconomic status including sufficient funding to pay for immunosuppressive medications post-transplant
- Current and past history of alcohol and substance use and abuse
- Current and past psychiatric history including baseline cognitive status and coping skills

- Mechanical ventilation. Refer to Medical Director.

- Patients with human immunodeficiency virus (HIV) infection must be on a highly active antiretroviral therapy (HAART) regimen and there must be documented evidence of sustained viral load suppression.

- BMI ≥ 30 kg/m².
  - Refer to requesting program Patient Selection Criteria.
  - If outside the program’s patient selection criteria, refer to Medical Director.

- BMI < 17 kg/m².
  - Refer to requesting program Patient Selection Criteria.
  - If outside the program’s patient selection criteria, refer to Medical Director.

- Gastrointestinal (GI) clearance may be indicated in patients with a history of complicated or active GI disorders.

- Severe or symptomatic osteoporosis.
  - Refer to requesting program Patient Selection Criteria

- Patients over the age of 65. (Weiss et al., 2008)
  - Refer to requesting program Patient Selection Criteria.
  - If outside the program’s patient selection criteria, refer to Medical Director.

- The presence of other medical comorbidities such as diabetes mellitus, osteoporosis, gastroesophageal reflux, and coronary artery disease must be assessed individually based on severity of disease, presence of end-organ damage, and ease of control with standard therapies. (Lee, 2010)

References


Heart/Lung

General Information

In 2019, 45 heart/lung transplants were completed, 2 of which were in children, according to the United Network for Organ Sharing (UNOS).

Indications

- Patients with end-stage pulmonary vascular disease with end-stage non-reversible cardiac disease secondary to one of the following:
  - Primary pulmonary hypertension.
  - Eisenmenger syndrome with a cardiac defect not correctable by surgical repair.
  - Patients who are appropriate for single or double lung transplantation and who have severe cardiac disease not otherwise treatable.
- Retransplantation. Usually due to primary graft failure (non-function of the grafted organ), rejection refractory to immunosuppressive therapy, bronchiolitis obliterans (chronic rejection) and coronary artery disease (graft vasculopathy).

EVALUATION AND MANAGEMENT GUIDELINES FOR PATIENTS WHO ARE POTENTIAL CANDIDATES FOR COMBINED HEART/LUNG TRANSPLANTATION ARE THOSE FOR HEART AND LUNG TRANSPLANTATION. SEE HEART and LUNG.

Reference

Appendix

National Kidney Foundation Definition of Chronic Kidney Disease (CKD)

- Kidney damage for ≥ 3 months, as defined by structural or functional abnormalities of the kidney, with or without decreased GFR, manifest by either:
  - Pathological abnormalities; or
  - Markers of kidney damage, including abnormalities in the composition of the blood or urine, or abnormalities in imaging tests
- GFR < 60 ml/min/1.73 m² for ≥ 3 months, with or without kidney damage
The following are approved changes incorporated into the revision numbers indicated below.

<table>
<thead>
<tr>
<th>Revision</th>
<th>Date, Description of Change, and Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>07/19/2012: New clinical guideline. Approved by Medical Technology Assessment Committee</td>
</tr>
<tr>
<td>1.0</td>
<td>08/14/2012: Approved by National Medical Care Management Committee</td>
</tr>
<tr>
<td>2.0</td>
<td>10/10/2013: Approved by Medical Technology Assessment Committee</td>
</tr>
<tr>
<td>2.0</td>
<td>10/16/2013: Approved by Complex Medical Conditions Policy Committee</td>
</tr>
<tr>
<td>2.0</td>
<td>11/12/2013: Approved by the National Medical Care Management Committee</td>
</tr>
<tr>
<td>3.0</td>
<td>08/07/2014: Approved by Medical Technology Assessment Committee</td>
</tr>
<tr>
<td>3.0</td>
<td>09/09/2014: Approved by National Medical Care Management Committee</td>
</tr>
<tr>
<td>4.0</td>
<td>08/25/2015: Annual review by Optum Solid Organ Transplantation Expert Panel</td>
</tr>
<tr>
<td>4.0</td>
<td>09/03/2015: Approved by Medical Technology Assessment Committee</td>
</tr>
<tr>
<td>4.0</td>
<td>10/13/2015: Approved by National Medical Care Management Committee</td>
</tr>
<tr>
<td>5.0</td>
<td>09/01/2016: Approved by Medical Technology Assessment Committee</td>
</tr>
<tr>
<td>5.0</td>
<td>09/13/2016: Approved by National Medical Care Management Committee</td>
</tr>
<tr>
<td>Version</td>
<td>Date</td>
</tr>
<tr>
<td>---------</td>
<td>------------</td>
</tr>
<tr>
<td>5.0</td>
<td>10/10/2016</td>
</tr>
<tr>
<td>6.0</td>
<td>09/07/2017</td>
</tr>
<tr>
<td>6.0</td>
<td>9/12/2017</td>
</tr>
<tr>
<td>6.0</td>
<td>9/20/2017</td>
</tr>
<tr>
<td>7.0</td>
<td>8/8/2018</td>
</tr>
<tr>
<td>7.0</td>
<td>10/9/2018</td>
</tr>
<tr>
<td>8.0</td>
<td>12/5/2018</td>
</tr>
<tr>
<td>8.0</td>
<td>1/10/2019</td>
</tr>
<tr>
<td>9.0</td>
<td>8/7/2019</td>
</tr>
<tr>
<td>10.0</td>
<td>1/15/20: Optum Solid Organ and Mechanical Circulatory Devices Expert Panel review of thoracic solid organ content.</td>
</tr>
<tr>
<td>10.0</td>
<td>3/19/20: Annual review of thoracic solid organ content. Approved by Medical Technology Assessment Committee.</td>
</tr>
<tr>
<td>11.0</td>
<td>7/29/20: Optum Solid Organ Transplantation Expert Panel review of abdominal organ content</td>
</tr>
</tbody>
</table>